Open access · CC-BY
via OpenAlex
Effects of the 5:2 intermittent fasting diet on non-alcoholic fatty liver disease: A randomized controlled trial
Hamed Kord‐Varkaneh, Ammar Salehi sahlabadi, Mihnea‐Alexandru Găman, Mohsen Rajabnia, Melahat Sedanur Macit, Heitor O. Santos, Azita Hekmatdoost
Frontiers in Nutrition · 2022 · ▲ 72 citations
Abstract
Background and aims Dietary regimens are crucial in the management of non-alcoholic fatty liver disease (NAFLD). The effects of intermittent fasting (IF) have gained attention in this regard, but further research is warranted. Thus, we aimed to ascertain the overall effects of the 5:2 IF diet (5 days a week of normal food intake and 2 consecutive fasting days) in patients with NAFLD compared to a control group (usual diet). Methods and results A 12-week randomized controlled trial was performed to evaluate the effects of the 5:2 IF diet on anthropometric indices, body composition, liver indices, serum lipids, glucose metabolism, and inflammatory markers in patients with NAFLD. The IF group ( n = 21) decreased body weight (86.65 ± 12.57–82.94 ± 11.60 kg), body mass index (30.42 ± 2.27–29.13 ± 1.95 kg/m 2 ), waist circumference (103.52 ± 6.42–100.52 ± 5.64 cm), fat mass (26.64 ± 5.43–23.85 ± 5.85 kg), fibrosis (6.97 ± 1.94–5.58 ± 1.07 kPa), steatosis scores/CAP (313.09 ± 25.45–289.95 ± 22.36 dB/m), alanine aminotransferase (41.42 ± 20.98–28.38 ± 15.21 U/L), aspartate aminotransferase (34.19 ± 10.88–25.95 ± 7.26 U/L), triglycerides (171.23 ± 39.88–128.04 ± 34.88 mg/dl), high-sensitivity C-reactive protein (2.95 ± 0.62 −2.40 ± 0.64 mg/L), and cytokeratin-18 (1.32 ± 0.06–1.19 ± 0.05 ng/ml) values compared to the baseline and the end of the control group ( n = 23)— p ≤ 0.05 were considered as significant. However, the intervention did not change the levels of high-density lipoprotein cholesterol, total cholesterol, low-density lipoprotein cholesterol, fasting blood sugar, insulin, HOMA-IR, and total antioxidant capacity. Conclusion Adhering to the 5:2 IF diet can reduce weight loss and related parameters (fat mass and anthropometric indicators of obesity), as well as hepatic steatosis, liver enzymes, triglycerides, and inflammatory biomarkers in patients with NAFLD.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3389/fnut.2022.948655
- Canonical
- link ↗
- Fetched
- 2026-06-15 MST
Cite this
APA
Kord‐Varkaneh, H., sahlabadi, A.S., Găman, M., Rajabnia, M., Macit, M.S., Santos, H.O., & Hekmatdoost, A. (2022). Effects of the 5:2 intermittent fasting diet on non-alcoholic fatty liver disease: A randomized controlled trial. <em>Frontiers in Nutrition</em>. https://doi.org/10.3389/fnut.2022.948655
Vancouver
Kord‐Varkaneh H, sahlabadi AS, Găman M, Rajabnia M, Macit MS, Santos HO, et al. Effects of the 5:2 intermittent fasting diet on non-alcoholic fatty liver disease: A randomized controlled trial. Frontiers in Nutrition. 2022. doi:10.3389/fnut.2022.948655.
BibTeX
@article{hamed2022Effect,
title = {Effects of the 5:2 intermittent fasting diet on non-alcoholic fatty liver disease: A randomized controlled trial},
author = {Hamed Kord‐Varkaneh and Ammar Salehi sahlabadi and Mihnea‐Alexandru Găman and Mohsen Rajabnia and Melahat Sedanur Macit and Heitor O. Santos and Azita Hekmatdoost},
journal = {Frontiers in Nutrition},
year = {2022},
doi = {10.3389/fnut.2022.948655},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
BMC Gastroenterology 2019
Open access · CC-BY
Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: a randomised controlled trial
Frontiers in Nutrition 2024
Open access · CC-BY
Effect of 5:2 intermittent fasting diet versus daily calorie restriction eating on metabolic-associated fatty liver disease—a randomized controlled trial
Nutrients 2020
Open access · CC-BY
Does the Energy Restriction Intermittent Fasting Diet Alleviate Metabolic Syndrome Biomarkers? A Randomized Controlled Trial
Clinical Liver Disease 2022
Open access · OA
Intermittent Fasting as a Treatment for Nonalcoholic Fatty Liver Disease: What Is the Evidence?
Clinical and Molecular Hepatology 2022
Open access · CC-BY
Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease
Wiadomości Lekarskie 2023
Open access · OA